Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
7 studies found for:    DIPAK
Show Display Options
Rank Status Study
1 Recruiting Study of Lanreotide to Treat Polycystic Kidney Disease
Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Intervention: Drug: Lanreotide
2 Recruiting Cardiovascular Longitudinal Evaluation & Assessment of Risk (CLEAR) Study
Condition: Cardiovascular Disease
Intervention:
3 Enrolling by invitation Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure
Condition: Heart Failure
Interventions: Drug: Beta blocker;   Other: Placebo
4 Terminated A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.
Condition: Seasonal Allergic Conjunctivitis to Ragweed
Intervention: Drug: Olopatadine
5 Active, not recruiting Alternative Risk Markers in Coronary Artery Disease (ARMCAD)
Condition: Coronary Artery Disease
Intervention:
6 Not yet recruiting Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)
Condition: Non-Small Cell Lung Cancer.
Intervention: Drug: ceritinib
7 Recruiting Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
Condition: Solid Tumors
Intervention: Drug: INC280

Indicates status has not been verified in more than two years